Wanitphakdeedecha Rungsima, Ungaksornpairote Chanida, Kaewkes Arisa, Rojanavanich Viboon, Phothong Weeranut, Manuskiatti Woraphong
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Bangkok Christian Hospital, Bangkok, Thailand.
J Cosmet Dermatol. 2016 Dec;15(4):452-457. doi: 10.1111/jocd.12289. Epub 2016 Sep 19.
Botulinum toxin type A (BTA) has been approved for the treatment of strabismus, blepharospasm, muscle spasm, cervical dystonia, pain syndrome, glabella wrinkles, and severe primary axillary hyperhidrosis. Intradermal injection of BTA has been used off-label by many clinicians for the purpose of face-lifting effect. Few studies on onabotulinumtoxinA (ONA) demonstrated no clinical efficacy on face-lifting effect when comparing to normal saline solution (NSS). So far, there is no split-face comparison study on face-lifting effect of abobotulinumtoxinA (ABO).
To determine the face-lifting effect of ABO intradermal injection and NSS.
Twenty-two subjects with symmetrical faces on both facial expression and expressionless were randomly injected with ABO at 1:7 cc dilution (500 unit or one vial in 7 cc of NSS) on one side and NSS on the other side using intradermal injection technique. Standardized photographic documentation was obtained at baseline, and at 2 weeks after treatment. The face-lifting effect was graded by two blinded dermatologists using photographic comparison and rated by the patients. Side effects were also recorded at the end of the study.
Face-lifting effect was demonstrated in 40.9% and 4.5% of patients with ABO and NSS, respectively. There was a statistically significant difference in face-lifting effect when comparing between ABO and NSS (P = 0.021). The face-lifting was reported in 50.0% of patients receiving ABO injection. The patients with oval-face shape tended to respond better with ABO (P = 0.046). The odd of face-lifting effect for patients aged younger than 32 was higher than patients aged older than 32 with the odds ratio of 7.9 and 95% confidence interval of 1.1-56.1. Facial asymmetry was found in 22.7% of subjects.
This study demonstrated the face-lifting effect of ABO intradermal injection. Patients with oval-face shape and aged younger than 32 tended to respond better. Therefore, patient selection should be emphasized to improve efficacy of this technique.
A型肉毒杆菌毒素(BTA)已被批准用于治疗斜视、眼睑痉挛、肌肉痉挛、颈部肌张力障碍、疼痛综合征、眉间皱纹和严重的原发性腋窝多汗症。许多临床医生将BTA皮内注射用于提升面部效果这一未获批准的用途。关于A型肉毒毒素(ONA)的少数研究表明,与生理盐水溶液(NSS)相比,其在提升面部效果方面无临床疗效。迄今为止,尚无关于阿柏西普肉毒毒素A(ABO)提升面部效果的半脸对照研究。
确定ABO皮内注射和NSS的面部提升效果。
22名面部表情和无表情时均对称的受试者,采用皮内注射技术,一侧随机注射1:7 cc稀释度的ABO(500单位或1瓶ABO溶于7 cc NSS中),另一侧注射NSS。在基线和治疗后2周获取标准化照片记录。由两名不知情的皮肤科医生通过照片对比对面部提升效果进行分级,并由患者进行评分。研究结束时还记录了副作用。
接受ABO和NSS治疗的患者中,面部提升效果分别为40.9%和4.5%。ABO和NSS之间在面部提升效果上存在统计学显著差异(P = 0.021)。接受ABO注射的患者中有50.0%报告有面部提升效果。椭圆形脸的患者对ABO的反应往往更好(P = 0.046)。32岁以下患者面部提升效果的几率高于32岁以上患者,优势比为7.9,95%置信区间为1.1 - 56.1。22.7%的受试者存在面部不对称。
本研究证明了ABO皮内注射的面部提升效果。椭圆形脸且年龄小于32岁的患者反应往往更好。因此,应强调患者选择以提高该技术的疗效。